SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS)
IONS 86.50+3.6%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SnowShredder who wrote (1853)3/28/1998 9:45:00 AM
From: Perry  Read Replies (2) of 4676
 
As far as I am aware antisense and ribozymes are very similar in their mechanism(s) of action. Antisense rely partly on their ability to initiate mRNA hydrolysis by stimulating RNase H activity within the cell, whereas ribozymes appear to initiate hydrolysis without an enzyme. Both technologies appear very promising.

As far as a delivery strategy is concerned, I talked to a ISIP toxicologist at this years annual Society of Toxicology meeting and was told that a carrier was not necessary for in vivo antisense delivery, however in cell culture (in vitro) liposome encapsulation is necessary. I do not believe there is a clear answer as to why this is the case.

Please let me know if you have heard anything different.

Perry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News